Company Overview and News
Foreign reinsurance companies have re-approached the insurance regulator seeking relaxation on the order of preference norms for reinsurance contracts before they come up for renewal on January 1. The Insurance Regulatory and Development Authority of India (IRDAI) had earlier upheld the practice of giving first preference to General Insurance Corporation of India (GIC Re) for any reinsurance contract.
HVRRY SSREY HVRRF SCR SSREF
As per the liquidity contract granted by SCOR SE to EXANE BNP PARIBAS, as at 30 June 2018 the following assets appeared on the liquidity account:
Au titre du contrat de liquidité confié par la société SCOR à EXANE BNP PARIBAS, en date de dénouement du 30 juin 2018, les moyens suivants figuraient au compte de liquidité :
PARIS (Reuters) - The United States has rejected a French request for waivers for its companies operating in Iran that Paris sought after President Donald Trump imposed sanctions on the Islamic Republic, French Finance Minister Bruno Le Maire told Le Figaro.
Replacing your chronological age with your biological age as a retirement plan input could help you improve decisions on how to save, invest and spend.
Toutes les résolutions proposées ont été adoptées par l'Assemblée Générale Mixte de SCOR du 26 avril 2018
The Combined General Meeting of SCOR SE was held on April 26, 2018 in Paris and was chaired by Mr. Denis Kessler, Chairman and Chief Executive Officer of SCOR SE.
Les actionnaires de la Société sont invités à participer à l'Assemblée Générale Mixte qui se tiendra le :
Thursday, April 26, 2018 at 10:00 at the headquarters of SCOR SE 5, avenue Kléber 75016 Paris
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:SCR / SCOR SE on message board site Silicon Investor.